MX2022006500A - Terapia de combinacion que involucra compuestos macrociclicos de diarilo. - Google Patents

Terapia de combinacion que involucra compuestos macrociclicos de diarilo.

Info

Publication number
MX2022006500A
MX2022006500A MX2022006500A MX2022006500A MX2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A
Authority
MX
Mexico
Prior art keywords
combination therapy
macrocyclic compounds
therapy involving
diaryl
diaryl macrocyclic
Prior art date
Application number
MX2022006500A
Other languages
English (en)
Spanish (es)
Inventor
Wei Deng
Dayong Zhai
Jingrong J Cui
Laura Rodon
Brion W Murray
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of MX2022006500A publication Critical patent/MX2022006500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022006500A 2019-11-27 2020-11-25 Terapia de combinacion que involucra compuestos macrociclicos de diarilo. MX2022006500A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962941026P 2019-11-27 2019-11-27
US202062981822P 2020-02-26 2020-02-26
US202063005681P 2020-04-06 2020-04-06
PCT/US2020/062390 WO2021108682A1 (en) 2019-11-27 2020-11-25 Combination therapy involving diaryl macrocyclic compounds

Publications (1)

Publication Number Publication Date
MX2022006500A true MX2022006500A (es) 2022-07-04

Family

ID=76129920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006500A MX2022006500A (es) 2019-11-27 2020-11-25 Terapia de combinacion que involucra compuestos macrociclicos de diarilo.

Country Status (12)

Country Link
US (2) US11654145B2 (https=)
EP (1) EP4065125A4 (https=)
JP (1) JP7670711B2 (https=)
KR (1) KR20220133866A (https=)
CN (1) CN114901286B (https=)
AU (1) AU2020391222A1 (https=)
BR (1) BR112022010278A2 (https=)
CA (1) CA3162632A1 (https=)
IL (1) IL293206A (https=)
MX (1) MX2022006500A (https=)
TW (1) TW202133855A (https=)
WO (1) WO2021108682A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021154929A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
US20220323446A1 (en) * 2021-03-17 2022-10-13 Amgen Inc. Sotorasib dosing regimen
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2025148858A1 (zh) * 2024-01-08 2025-07-17 应世生物科技(南京)有限公司 FAK抑制剂和Pan-RAS抑制剂
WO2025157162A1 (zh) * 2024-01-22 2025-07-31 应世生物科技(南京)有限公司 Fak抑制剂与kras g12c抑制剂的联用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AU2016287568B2 (en) * 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
EP3368039A1 (en) * 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
ES3017461T3 (en) 2018-09-10 2025-05-13 Mirati Therapeutics Inc Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
MX2022006366A (es) * 2019-11-27 2022-06-22 Turning Point Therapeutics Inc Terapia de combinacion que implica compuestos de diarilo macrociclico.
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
EP4065125A4 (en) 2024-01-03
JP2023505056A (ja) 2023-02-08
IL293206A (en) 2022-07-01
AU2020391222A1 (en) 2022-06-30
US11654145B2 (en) 2023-05-23
US20240033266A1 (en) 2024-02-01
CA3162632A1 (en) 2021-06-03
CN114901286B (zh) 2024-05-10
WO2021108682A1 (en) 2021-06-03
KR20220133866A (ko) 2022-10-05
CN114901286A (zh) 2022-08-12
EP4065125A1 (en) 2022-10-05
JP7670711B2 (ja) 2025-04-30
US20210220364A1 (en) 2021-07-22
TW202133855A (zh) 2021-09-16
BR112022010278A2 (pt) 2022-10-04

Similar Documents

Publication Publication Date Title
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
CL2022001671A1 (es) Inhibidores de sos1
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CL2019001551A1 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX393974B (es) Terapia de combinacion para tratamiento de cancer.
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
MX2014001218A (es) Tratamiento de cancer de mama.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX369609B (es) Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
CO2022000481A2 (es) Inhibidores de enzimas
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CL2020002604A1 (es) Ciertos compuestos de pladienolida y métodos de uso.
PH12017501879A1 (en) Methods for treating cancer
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
EA202091694A1 (ru) Ингибиторы pd-1/pd-l1